Nanobiotix gains EU patent for anticancer platform September 23, 2008: Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced that the European Patent Office (EPO) has issued Patent No. 1744789 to the company, related to its “novel activable particles that can be used in the health sector.” More specifically, the patent protects “composite particles that can generate free radicals or heat when excited by X-rays, and to the uses thereof in health, particularly human. The inventive particles comprise an inorganic-based, and optionally organic-based, nucleus and can be activated in vivo, in order to label or alter cells, tissues or organs. (The patent protection) also relates to methods for the production of said particles, and to pharmaceutical or diagnostic compositions containing same.” “We are extremely pleased that our platform technology, nanoXray, is now patent-protected throughout the European Union. We are hopeful that we will soon receive similar patent protection in the United States as well,” said Laurent Levy, president and CEO of Nanobiotix and co-president of the French Technology Platform on Nanomedicine (FTPN). “NanoXray is designed to allow the precise destruction of cancer cells via the controlled application of an outside-the-body energy source-a standard X-ray. Protecting this intellectual property is key to long-term commercial success.” “The nanoXray platform allows for the controlled generation of physical reactions in targeted cells when triggered by the application of an external energy source – a standard X-ray. This may have significant ramifications for cancer therapy in the not-too-distant future,” added Paras N. Prasad, co-founder of Nanobiotix and executive director of the Institute for Lasers, Photonics and Biophotonics at SUNY (Buffalo).